59 / 1851
Changing nature of early development trials
•
Enrichment strategies: by subtype of by genomic
alterations
•
Novel dose escalation methods applied
•
Research biopsies
•
Driving go-no-go decisions based on their ability to
provide proof of concept
•
Trends in increase in the sample size of phase I trials
•
Expanding cohorts being conducted for multiple
purposes